Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination therapy for the treatment of diabetes

a combination therapy and diabetes technology, applied in the field of diabetes treatment, can solve the problems of costly disease, diabetes medications that are associated with various disadvantages, kidney failure, blindness, etc., and achieve the effects of preventing, treating, reducing, reducing, and/or reducing the causes and/or symptoms of diabetic conditions and associated complications

Inactive Publication Date: 2013-05-14
THERAKOS INC
View PDF27 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention provides a way to treat diabetic conditions and complications by giving patients telenzepine and sertraline. This helps to reduce symptoms associated with diabetes, such as high blood glucose levels and decreased insulin production. The methods involve measuring the decrease in symptoms using various tests. Overall, the invention offers a promising treatment option for diabetics.

Problems solved by technology

Diabetes is also among the leading causes of kidney failure, blindness, visual disability, and non-traumatic amputation of the lower limbs.
The chronic nature of diabetes also makes it a costly disease.
However, existing diabetes medications are associated with various disadvantages such as side effects, short half-life, and / or negative interactions with other drugs.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapy for the treatment of diabetes
  • Combination therapy for the treatment of diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

I. Introduction

[0044]The present invention is based, in part, on the surprising discovery that the combined administration of telenzepine and sertraline is useful in reducing, treating, ameliorating, and / or preventing symptoms of diabetes. By co-administering to a subject in need thereof a therapeutic or subtherapeutic dose of each of telenzepine and sertraline, the symptoms of diabetes can be treated, ameliorated and / or improved. Additionally, with administration of therapeutic or prophylactic regimes of telenzepine and sertraline, markers that are indicative of diabetic conditions, such as blood glucose levels, HbA1c levels, and C-peptide levels can be modulated to indicate amelioration or reduction of disease symptoms. By co-administering to a subject in need thereof a therapeutic or subtherapeutic dose of each of telenzepine and sertraline, blood levels of glucose and / or HbA1c (glycosylated hemoglobin) can be reduced to below threshold levels, and C-peptide levels in the blood c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

The present invention provides methods of treating, reducing, preventing, or inhibiting symptoms of diabetes and / or lowering plasma levels of HbA1c by co-administration of therapeutic or subtherapeutic doses of telenzepine and sertraline to a subject in need thereof.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application No. 61 / 356,779 filed Jun. 21, 2010, the content of which is incorporated herein by reference in its entirety.FIELD OF THE INVENTION[0002]The present invention provides methods for treating diabetes and associated complications by co-administration of sertraline and telenzepine.BACKGROUND OF THE INVENTION[0003]In 2003, the International Diabetes Foundation estimated that there were 194 million people worldwide with diabetes mellitus. It further estimated that another 314 million people worldwide had impaired glucose tolerance or “pre-diabetes,” a condition that often precedes diabetes. Both of these figures are expected to rise significantly by the year 2025. In the United States alone, it is estimated that 23.6 million children and adults—nearly 8% of the country's population—have diabetes, while another 57 million people have pre-diabetes.[0004]Diabetes mellitus (“diabet...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(United States)
IPC IPC(8): A61K31/55
CPCA61K31/135A61K31/5513A61K2300/00A61P3/00A61P7/00A61P3/10
Inventor SEED, BRIANMECHANIC, JORDAN
Owner THERAKOS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com